Evidence map›Paper›PMID 41744852›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma.

Thomas Samson, Maral Aali, Darien McBride, Thomas Arnason, Sharon E Clarke, Ravi Ramjeesingh, Lisette Gonzalez-Chavez, Yara Azizieh, Mark J Walsh, Scott M Livingstone and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thomas SamsonFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0009-0002-7340-5642
Maral AaliFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Darien McBrideFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0009-0004-1288-2888
Thomas ArnasonFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0001-5038-6202
Sharon E ClarkeFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0001-5759-5808
Ravi RamjeesinghFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0001-5584-3505
Lisette Gonzalez-ChavezDepartment of Surgery, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Yara AziziehDepartment of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0009-0001-3441-4506
Mark J WalshFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Scott M LivingstoneFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0001-9241-7548
Stephanie E HiebertFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Jeanette E BoudreauDepartment of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0003-0203-2180
Boris L Gala-LopezFaculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada.ORCID 0000-0003-1179-2085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection combined with chemotherapy offers the best chance of survival in pancreatic ductal adenocarcinoma (PDAC), but many will experience recurrence and early mortality. We examined soluble AXL (sAXL), a blood protein, for its ability to predict 6-month mortality after resection and compared it to CA19-9. Fifty-four patients with PDAC who underwent tumour resection were analyzed to assess biomarker performance and identify optimal cut-off levels. The cut-off for sAXL was 40.26 ng/mL (sensitivity 0.729; specificity 0.643), while it 253.3 U/mL for CA19-9 (sensitivity 0.591; specificity 0.621). Patients with sAXL > 40.26 ng/mL had a non-significant trend toward worse survival (log-rank

Indexed as

AXL receptor tyrosine kinaseCA19-9early mortalitypancreatic ductal adenocarcinomapreoperative risk stratificationprognostic biomarkersAXL

Identifiers

PMID41744852
PMCPMC12939350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.